Abivax SA (ABVX)
85.41
-1.60
(-1.84%)
USD |
NASDAQ |
Oct 08, 13:11
Abivax Shareholders Equity (Quarterly) : 418.75M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 418.75M |
| March 31, 2026 | 494.98M |
| December 31, 2025 | 534.62M |
| Date | Value |
|---|---|
| September 30, 2025 | 600.70M |
| June 30, 2025 | -56.67M |
| March 31, 2025 | -7.121M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Poxel SA | -- |
| OSE Immunotherapeutics SA | -- |
| Cogent Biosciences, Inc. | 532.39M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 528.44M |
| Total Liabilities (Quarterly) | 109.69M |
| Debt to Equity Ratio | 0.0033 |
| Current Ratio | 5.965 |
| Net Debt Paydown Yield | 0.19% |